Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Physiomics Plc (PYC.L)
GBp0.55
+0.00 (+0.00%)
GB LSE Healthcare Biotechnology
Address
The Magdalen Centre OX4 4GA
Oxford, GB
Oxford, GB
CEO
Peter Joseph Sargent
Website
physiomics.co.uk
IPO
2004-12-20
ISIN GB00BDR6W943
Description
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp0.55
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
1.03
Float Shares
360.72M
Free Float %
107.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.70% | +7.69% | +40.00% | +47.37% | +86.67% | +145.61% | +68.67% | -67.44% | -89.31% | -78.79% | -99.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.55
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-15.88
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+44.3% ★ Q4'25: +30.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+62.2% ★ Q4'25: +33.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-73.0% Q4'25: -41.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-58.3% Q4'25: -71.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-198.0% Q4'25: -969.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+75.9% Q4'25: +124.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2012 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
135.3K
est: 284.2K (-52.4%)
|
235.5K
est: 235.0K (+0.2%)
|
297.1K
est: 803.0K (-63.0%)
|
512.9K
est: 500.0K (+2.6%)
|
783.1K
est: 750.0K (+4.4%)
|
799.1K
est: 900.0K (-11.2%)
|
702.3K
est: 750.0K (-6.4%)
|
830.3K
est: 855.0K (-2.9%)
|
597.4K
est: 597.0K (+0.1%)
|
543.3K
est: 600.0K (-9.5%)
|
784.0K
est: 834.0K (-6.0%)
|
1.00M
1.00M – 1.00M
+19.9% YoY
|
| EBITDA |
-564.4K
est: -192.8K (-192.7%)
|
-407.8K
est: -471.4K (+13.5%)
|
-425.0K
est: -544.9K (+22.0%)
|
-257.2K
est: -883.9K (+70.9%)
|
-192.8K
est: -508.9K (+62.1%)
|
-124.7K
est: -610.7K (+79.6%)
|
-324.5K
est: -508.9K (+36.2%)
|
-347.8K
est: -158.6K (-119.3%)
|
-561.6K
est: -405.1K (-38.6%)
|
-659.8K
est: -407.1K (-62.1%)
|
-448.2K
est: -565.9K (+20.8%)
|
-678.6K
-678.6K – -678.6K
-19.9% YoY
|
| EBIT |
-572.2K
est: -196.3K (-191.6%)
|
-414.5K
est: -497.1K (+16.6%)
|
-431.4K
est: -554.5K (+22.2%)
|
-260.4K
est: -932.1K (+72.1%)
|
-201.2K
est: -517.9K (+61.2%)
|
-134.4K
est: -621.5K (+78.4%)
|
-337.0K
est: -517.9K (+34.9%)
|
-359.1K
est: -172.5K (-108.1%)
|
-572.0K
est: -412.3K (-38.7%)
|
-668.7K
est: -414.4K (-61.4%)
|
-457.3K
est: -575.9K (+20.6%)
|
-690.6K
-690.6K – -690.6K
-19.9% YoY
|
| Net Income |
-539.6K
est: -10.55M (+94.9%)
|
-357.7K
est: -462.9K (+22.7%)
|
-378.7K
est: 2.38M (-115.9%)
|
-183.3K
est: -867.9K (+78.9%)
|
-104.0K
est: -666.9K (+84.4%)
|
-64.4K
est: -238.2K (+72.9%)
|
-215.8K
est: -500.1K (+56.8%)
|
-253.1K
est: -82.7K (-206.0%)
|
-477.3K
est: -1.17M (+59.1%)
|
-609.4K
est: -1.07M (+43.1%)
|
-415.3K
est: -333.4K (-24.5%)
|
-238.2K
-238.2K – -238.2K
+28.6% YoY
|
| SGA |
—
est: 4.6K (-100.0%)
|
19.4K
est: 3.8K (+409.6%)
|
37.2K
est: 13.0K (+185.8%)
|
—
est: 8.1K (-100.0%)
|
14.4K
est: 12.2K (+18.6%)
|
14.0K
est: 14.6K (-4.1%)
|
10.5K
est: 12.2K (-13.7%)
|
10.5K
est: 13.9K (-24.3%)
|
11.0K
est: 9.7K (+13.8%)
|
11.3K
est: 9.7K (+15.6%)
|
11.3K
est: 13.5K (-16.8%)
|
16.2K
16.2K – 16.2K
+19.9% YoY
|
| EPS |
-0.05
est: -0.04 (-1.8%)
|
-0.02
est: -0.02 (+15.0%)
|
-0.01
est: 0.01 (-230.0%)
|
0.00
est: -0.01 (+38.5%)
|
0.00
est: 0.00 (+50.0%)
|
0.00
est: 0.00 (+10.0%)
|
0.00
est: 0.00 (-4.8%)
|
0.00
est: 0.00 (+16.1%)
|
0.00
est: 0.00 (+0.0%)
|
0.00
est: 0.00 (+0.0%)
|
0.00
est: 0.00 (-21.4%)
|
0.00
0.00 – 0.00
+28.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-965.9K
OE per share TTM
-0.15
Owner's Yield
-45.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-41.6K
Shares Outstanding
336.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Sargent | CEO & COO | 164.6K | — |
| Hayley Close | Head of Business Development | — | female |
| Ian Russell Bagnall | Company Secretary, Finance Director & Non-Executive Director | — | male |
| Anthony Louis Clayden | Head of Finance & Company Secretary | — | male |
| Michael David Whitlow | Executive Director | — | male |
| Venkata Putcha | Head of Biostatistics | — | — |
| Jesse Thissen | Head of Biometrics | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PYC.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
